Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
5 hedge funds and large institutions have $66 invested in Sorrento Therapeutics, Inc. in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
77% less capital invested
Capital invested by funds: $287 → $66 (-$221)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KWA
Kingswood Wealth Advisors
San Diego,
California
|
+$32 |
Top Sellers
SRNE Hedge Fund Activity: Q4 2024 in Review
5 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2024, worth a combined $66 — down 77% from $287 a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SRNE positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kingswood Wealth Advisors, opening a new position worth an estimated $32.
- 5 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2024, up from 4 in Q3 2024.
- Funds reported $66 of Sorrento Therapeutics, Inc. stock for Q4 2024, down 77% quarter-over-quarter.
- 2 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Sorrento Therapeutics, Inc. buyer in Q4 2024 was Kingswood Wealth Advisors, an estimated $32 added.
Based on aggregated 13F filings for Q4 2024.